cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.qr44sk
title: Occurrence Download

description: A dataset containing 2505 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Trechispora mollusca (Pers.) Liberta, Trechispora stevensonii (Berk. & Broome) K.H.Larss.)",
 "Geometry POLYGON((-9.36035 44.71551,-10.59082 42.81152,-11.82129 36.80928,-7.69043 36.17336,-3.38379 35.88905,3.12012 38.13456,9.18457 38.20366,11.7334 37.16032,12.78809 34.74161,17.09473 33.79741, 23.15918 34.23451,30.10254 32.62087,33.2666 32.99024,35.72754 35.03,33.00293 35.53223,28.69629 35.17381,28.34473 36.31513,25.7959 37.50973,24.91699 39.90974,28.78418 40.6473,30.71777 41.17865,36.87012 45.213,38.18848 46.98025,38.71582 47.7541,39.94629 47.93107,40.20996 49.61071,37.0459 50.34546,35.72754 50.40152,33.79395 52.26816,31.68457 51.94426,31.4209 53.27835,32.56348 53.43572,30.98145 54.77535,30.89355 55.52863,28.43262 56.02295,27.20215 57.65716,27.37793 58.30949,27.90527 59.17593,29.66309 59.88894,27.6416 60.58697,31.50879 62.75473,28.78418 69.83962,30.89355 70.28912,29.22363 71.55274,21.75293 71.30079,14.28223 70.14036,11.38184 67.47492,4.87793 63.66576,-5.53711 71.52491,-10.63477 71.69129,-21.5332 67.74276,-28.56445 65.36684,-24.3457 61.35461,-9.36035 44.71551))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "Year is greater than or equal to 1980",
 "Year is less than or equal to 2021"
 ]
}

 The dataset includes 2505 records from 80 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0255076-210914110416597/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25549/pcra-c14-3957
title: Baptist, vol. [10], no. 5-6 (March 1926)

description: [description english/roman)] Biweekly
DOI: 10.15468/dl.dbftdu
title: Occurrence Download

description: A dataset containing 107 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Rubus hebecarpus P.J.Müll."
 ]
}

 The dataset includes 107 records from 7 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0106087-230530130749713/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25549/pcra-c14-6322
title: Baptist Ukrainy = [Ukrainian Baptist], no. 12 (December 1928)

description: [description english/roman)] Monthly
DOI: 10.15468/dl.4zchnc
title: Occurrence Download

description: A dataset containing 48887 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Canis latrans Say, 1823"
 ]
}

 The dataset includes 48887 records from 191 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0107580-210914110416597/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.mmujnd
title: Occurrence Download

description: A dataset containing 1363678 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Philippines",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present"
 ]
}

 The dataset includes 1363678 records from 765 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0255521-210914110416597/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.29039874
title: Diagnostic Biomarkers for Uveitis: Serum BAFF and CXCL9 in Differentiating Ocular Sarcoidosis, Tuberculosis and Other Entities with Implication for QuantiFERON-Positive Uveitis

description: To evaluate serum B cell activating factor (BAFF) and CXCL9 as diagnostic biomarkers for ocular sarcoidosis and ocular tuberculosis (TB). We also explore their role in the stratification of patients with QuantiFERON (QFT)-positive uveitis without another identifiable cause. Eighty uveitis patients with various entities were included: 10 with ocular sarcoidosis, 35 with TB-related uveitis (including 11 confirmed (ocular TB) and 24 QFT-positive uveitis of unknown cause) and 35 with other uveitis entities. Levels of serum BAFF and CXCL9 were measured. Serum BAFF was higher in ocular sarcoidosis compared to other groups (area under the curve (AUC) = 0.74; 95% CI: 0.53–0.96, <i>p</i> = 0.017). At an optimal serum BAFF cut-off point of 772.3 pg/ml, the sensitivity was 70.0% (95% CI: 39.7–89.2) and the specificity was 89.1% (95% CI: 77.0–95.3). Serum CXCL9 was comparable between ocular sarcoidosis and confirmed ocular TB but was significantly higher in these groups compared to other uveitis entities (AUC = 0.71, 95% CI: 0.57–0.86, <i>p</i> = 0.011). To differentiate ocular sarcoidosis and TB from other uveitis entities, CXCL9 (cutoff: 105.5 pg/ml) showed a sensitivity of 88.9% (95% CI: 67.2–98.0) and a specificity of 54.3% (95% CI: 38.2–69.5). High CXCL9 TB-related uveitis patients demonstrated a higher proportion of uveitis resolution when fully treated with antitubercular treatment (ATT) (<i>p</i> = 0.027). Serum BAFF and CXCL9 serve as potential diagnostic biomarkers for differentiating ocular sarcoidosis, ocular TB and other uveitis entities. These might identify QFT-positive uveitis who are most in need of ATT.
DOI: 10.6084/m9.figshare.29039874.v2
title: Diagnostic Biomarkers for Uveitis: Serum BAFF and CXCL9 in Differentiating Ocular Sarcoidosis, Tuberculosis and Other Entities with Implication for QuantiFERON-Positive Uveitis

description: To evaluate serum B cell activating factor (BAFF) and CXCL9 as diagnostic biomarkers for ocular sarcoidosis and ocular tuberculosis (TB). We also explore their role in the stratification of patients with QuantiFERON (QFT)-positive uveitis without another identifiable cause. Eighty uveitis patients with various entities were included: 10 with ocular sarcoidosis, 35 with TB-related uveitis (including 11 confirmed (ocular TB) and 24 QFT-positive uveitis of unknown cause) and 35 with other uveitis entities. Levels of serum BAFF and CXCL9 were measured. Serum BAFF was higher in ocular sarcoidosis compared to other groups (area under the curve (AUC) = 0.74; 95% CI: 0.53–0.96, <i>p</i> = 0.017). At an optimal serum BAFF cut-off point of 772.3 pg/ml, the sensitivity was 70.0% (95% CI: 39.7–89.2) and the specificity was 89.1% (95% CI: 77.0–95.3). Serum CXCL9 was comparable between ocular sarcoidosis and confirmed ocular TB but was significantly higher in these groups compared to other uveitis entities (AUC = 0.71, 95% CI: 0.57–0.86, <i>p</i> = 0.011). To differentiate ocular sarcoidosis and TB from other uveitis entities, CXCL9 (cutoff: 105.5 pg/ml) showed a sensitivity of 88.9% (95% CI: 67.2–98.0) and a specificity of 54.3% (95% CI: 38.2–69.5). High CXCL9 TB-related uveitis patients demonstrated a higher proportion of uveitis resolution when fully treated with antitubercular treatment (ATT) (<i>p</i> = 0.027). Serum BAFF and CXCL9 serve as potential diagnostic biomarkers for differentiating ocular sarcoidosis, ocular TB and other uveitis entities. These might identify QFT-positive uveitis who are most in need of ATT.
DOI: 10.6084/m9.figshare.29039874.v1
title: Diagnostic Biomarkers for Uveitis: Serum BAFF and CXCL9 in Differentiating Ocular Sarcoidosis, Tuberculosis and Other Entities with Implication for QuantiFERON-Positive Uveitis

description: To evaluate serum B cell activating factor (BAFF) and CXCL9 as diagnostic biomarkers for ocular sarcoidosis and ocular tuberculosis (TB). We also explore their role in the stratification of patients with QuantiFERON (QFT)-positive uveitis without another identifiable cause. Eighty uveitis patients with various entities were included: 10 with ocular sarcoidosis, 35 with TB-related uveitis (including 11 confirmed (ocular TB) and 24 QFT-positive uveitis of unknown cause) and 35 with other uveitis entities. Levels of serum BAFF and CXCL9 were measured. Serum BAFF was higher in ocular sarcoidosis compared to other groups (area under the curve (AUC) = 0.74; 95% CI: 0.53–0.96, <i>p</i> = 0.017). At an optimal serum BAFF cut-off point of 772.3 pg/ml, the sensitivity was 70.0% (95% CI: 39.7–89.2) and the specificity was 89.1% (95% CI: 77.0–95.3). Serum CXCL9 was comparable between ocular sarcoidosis and confirmed ocular TB but was significantly higher in these groups compared to other uveitis entities (AUC = 0.71, 95% CI: 0.57–0.86, <i>p</i> = 0.011). To differentiate ocular sarcoidosis and TB from other uveitis entities, CXCL9 (cutoff: 105.5 pg/ml) showed a sensitivity of 88.9% (95% CI: 67.2–98.0) and a specificity of 54.3% (95% CI: 38.2–69.5). High CXCL9 TB-related uveitis patients demonstrated a higher proportion of uveitis resolution when fully treated with antitubercular treatment (ATT) (<i>p</i> = 0.027). Serum BAFF and CXCL9 serve as potential diagnostic biomarkers for differentiating ocular sarcoidosis, ocular TB and other uveitis entities. These might identify QFT-positive uveitis who are most in need of ATT.
DOI: 10.6084/m9.figshare.29631033
title: Optic Neuritis Associated with Herpes Zoster Ophthalmicus: A Systematic Review and Analysis

description: To systematically review and analyze reported cases of herpes zoster ophthalmicus (HZO)-related optic neuritis (ON) without retinal involvement, a potentially sight-threatening complication of varicella-zoster virus (VZV). A PRISMA-guided search of online databases from inception to January 31, 2025, identified case reports and series describing HZO-related ON without retinal involvement. Study quality was assessed using Joanna Briggs Institute checklists. Data on demographics, clinical features, diagnostics, treatments, and outcomes were analyzed using SPSS. Thirty-two studies (1919–2025) comprising 38 patients were included. The mean patient age was 52.6 years (ranging from 6 to 82), with a near-equal gender distribution. Comorbid conditions such as human immunodeficiency virus (HIV) infection, diabetes, and autoimmune disorders were noted in one-third of cases. ON most commonly presented unilaterally and ipsilateral to the dermatome of HZO. The mean interval from HZO onset to ON was approximately 22 days (ranging from 10 days prior to 150 days afterward). Blurred vision and eye pain were the most frequent symptoms. Common signs include visual field defect, congestion, mydriasis, and ophthalmoplegia. Keratitis was the most common observation in slit-lamp examination (62.8% (22 of 35 cases)). Corticosteroid therapy, including high-dose and pulse regimens, was administered in a third-fourth (28 of 38) of patients. In outcome assessment, 52.8% (19 of 36) achieved mild or no impairment, while 36.3% (12 of 36) experienced clinical blindness. HZO-related ON is an uncommon but significant sight-threatening complication in HZO. Timely diagnosis and appropriate antiviral treatment along with corticosteroid therapy may improve the visual prognosis.
DOI: 10.6084/m9.figshare.29631033.v1
title: Optic Neuritis Associated with Herpes Zoster Ophthalmicus: A Systematic Review and Analysis

description: To systematically review and analyze reported cases of herpes zoster ophthalmicus (HZO)-related optic neuritis (ON) without retinal involvement, a potentially sight-threatening complication of varicella-zoster virus (VZV). A PRISMA-guided search of online databases from inception to January 31, 2025, identified case reports and series describing HZO-related ON without retinal involvement. Study quality was assessed using Joanna Briggs Institute checklists. Data on demographics, clinical features, diagnostics, treatments, and outcomes were analyzed using SPSS. Thirty-two studies (1919–2025) comprising 38 patients were included. The mean patient age was 52.6 years (ranging from 6 to 82), with a near-equal gender distribution. Comorbid conditions such as human immunodeficiency virus (HIV) infection, diabetes, and autoimmune disorders were noted in one-third of cases. ON most commonly presented unilaterally and ipsilateral to the dermatome of HZO. The mean interval from HZO onset to ON was approximately 22 days (ranging from 10 days prior to 150 days afterward). Blurred vision and eye pain were the most frequent symptoms. Common signs include visual field defect, congestion, mydriasis, and ophthalmoplegia. Keratitis was the most common observation in slit-lamp examination (62.8% (22 of 35 cases)). Corticosteroid therapy, including high-dose and pulse regimens, was administered in a third-fourth (28 of 38) of patients. In outcome assessment, 52.8% (19 of 36) achieved mild or no impairment, while 36.3% (12 of 36) experienced clinical blindness. HZO-related ON is an uncommon but significant sight-threatening complication in HZO. Timely diagnosis and appropriate antiviral treatment along with corticosteroid therapy may improve the visual prognosis.
DOI: 10.6084/m9.figshare.29464591
title: Efficacy of Intravitreal Dexamethasone Implant in Vitrectomized vs. Non-Vitrectomized Eyes: A Systematic Review and Meta-Analysis

description: We conducted this present meta-analysis to examine the difference in efficacy and safety of intravitreal dexamethasone implant (DEXI) in vitrectomized and non-vitrectomized eyes. All types of comparative studies published on PubMed, CENTRAL, Scopus, and Embase databases till March 10, 2025 were included. We conducted a random-effects meta-analysis for change in central macular thickness (CMT), best corrected visual acuity (BCVA) (as logMar), and rise in intraocular pressure (IOP). Thirteen studies were included comparing 365 vitrectomized eyes with 778 non-vitrectomized eyes. Studies included mixed etiologies of macular edema. Meta-analysis showed that change in CMT was not significantly different between the two groups at 1 month (MD: −11.34 95% CI: −47.51, 24.82 I<sup>2</sup> = 2%), 3 months (MD: −0.43 95% CI: −33.36, 32.5 I<sup>2</sup> = 44%), 6 months (MD: −0.69 95% CI: −33.57, 34.95 I<sup>2</sup> = 18%) or 12 months ((MD: 37.46 95% CI: −4.86, 79.77 I<sup>2</sup> = 86%). The pooled analysis found no statistically significant difference between the two groups for change in BCVA at 1 month (MD: 0.04 95% CI: −0.01, 0.09 I<sup>2</sup> = 32%), 3 months (MD: 0.04 95% CI: −0.02, 0.09 I<sup>2</sup> = 0%) and 6 months (MD: 0.06 95% CI: 0.00, 0.11 I<sup>2</sup> = 0%). However, change in BCVA was significantly higher in the vitrectomized group at 12 months (MD: 0.17 95% CI: 0.13, 0.22 I<sup>2</sup> = 54%). The meta-analysis found no statistically significant difference in the risk of a rise in IOP between the two groups (OR: 1.26 95% CI: 0.81, 1.95 I<sup>2</sup> = 0%). Subgroup analysis based on etiology did not change the results. DEXI may be equally efficacious and safe in vitrectomized and non-vitrectomized eyes.
DOI: 10.6084/m9.figshare.29464591.v1
title: Efficacy of Intravitreal Dexamethasone Implant in Vitrectomized vs. Non-Vitrectomized Eyes: A Systematic Review and Meta-Analysis

description: We conducted this present meta-analysis to examine the difference in efficacy and safety of intravitreal dexamethasone implant (DEXI) in vitrectomized and non-vitrectomized eyes. All types of comparative studies published on PubMed, CENTRAL, Scopus, and Embase databases till March 10, 2025 were included. We conducted a random-effects meta-analysis for change in central macular thickness (CMT), best corrected visual acuity (BCVA) (as logMar), and rise in intraocular pressure (IOP). Thirteen studies were included comparing 365 vitrectomized eyes with 778 non-vitrectomized eyes. Studies included mixed etiologies of macular edema. Meta-analysis showed that change in CMT was not significantly different between the two groups at 1 month (MD: −11.34 95% CI: −47.51, 24.82 I<sup>2</sup> = 2%), 3 months (MD: −0.43 95% CI: −33.36, 32.5 I<sup>2</sup> = 44%), 6 months (MD: −0.69 95% CI: −33.57, 34.95 I<sup>2</sup> = 18%) or 12 months ((MD: 37.46 95% CI: −4.86, 79.77 I<sup>2</sup> = 86%). The pooled analysis found no statistically significant difference between the two groups for change in BCVA at 1 month (MD: 0.04 95% CI: −0.01, 0.09 I<sup>2</sup> = 32%), 3 months (MD: 0.04 95% CI: −0.02, 0.09 I<sup>2</sup> = 0%) and 6 months (MD: 0.06 95% CI: 0.00, 0.11 I<sup>2</sup> = 0%). However, change in BCVA was significantly higher in the vitrectomized group at 12 months (MD: 0.17 95% CI: 0.13, 0.22 I<sup>2</sup> = 54%). The meta-analysis found no statistically significant difference in the risk of a rise in IOP between the two groups (OR: 1.26 95% CI: 0.81, 1.95 I<sup>2</sup> = 0%). Subgroup analysis based on etiology did not change the results. DEXI may be equally efficacious and safe in vitrectomized and non-vitrectomized eyes.
DOI: 10.6084/m9.figshare.28960259
title: A Novel Diagnostic and Subtype Classification Model Based on RNA N6-Methyladenosine Regulators for Behçet’s Uveitis

description: To investigate the role of RNA N6-methyladenosine (m<sup>6</sup>A) regulators in the diagnosis and subtype classification of Behçet’s uveitis, aiming to establish a novel predictive model and explore distinct molecular patterns for personalized therapeutic approaches. Data from the Gene Expression Omnibus GSE209567 dataset comprising 22 Behçet’s uveitis patients and 15 controls were analyzed for m<sup>6</sup>A regulator expression. Differentially expressed genes were identified using the “limma” R package, followed by random forest (RF) and support vector machine (SVM) model construction to select critical m6A regulators. A nomogram model was developed for prediction, and consensus clustering identified distinct m<sup>6</sup>A and gene-regulating patterns. Immune cell infiltration analysis was conducted using ssGSEA, and m<sup>6</sup>A scores were computed to quantify molecular patterns. Eleven m<sup>6</sup>A regulators were significantly differentially expressed. The top four candidate m<sup>6</sup>A regulators (FTO, YTHDF2, CBLL1, and METTL14) were identified to predict the risk of Behçet’s uveitis. A nomogram was constructed based on the four candidate m<sup>6</sup>A regulators to visualize the association between the expression levels of the candidate with the risk of onset of Behçet’s uveitis. Two distinct m<sup>6</sup>A patterns and gene patterns were identified, validated by consensus clustering. High m<sup>6</sup>A scores were associated with more severe disease stages, with differential immune cell infiltration observed between subtypes. Immune-related genes, such as LRRN3 and DAAM2, were identified as key in differentiating m<sup>6</sup>A patterns. M<sup>6</sup>A modification plays an important role in the occurrence of uveitis. Distinct m<sup>6</sup>A patterns and gene clusters highlight their potential for early diagnosis and personalized treatment.
DOI: 10.6084/m9.figshare.28960259.v1
title: A Novel Diagnostic and Subtype Classification Model Based on RNA N6-Methyladenosine Regulators for Behçet’s Uveitis

description: To investigate the role of RNA N6-methyladenosine (m<sup>6</sup>A) regulators in the diagnosis and subtype classification of Behçet’s uveitis, aiming to establish a novel predictive model and explore distinct molecular patterns for personalized therapeutic approaches. Data from the Gene Expression Omnibus GSE209567 dataset comprising 22 Behçet’s uveitis patients and 15 controls were analyzed for m<sup>6</sup>A regulator expression. Differentially expressed genes were identified using the “limma” R package, followed by random forest (RF) and support vector machine (SVM) model construction to select critical m6A regulators. A nomogram model was developed for prediction, and consensus clustering identified distinct m<sup>6</sup>A and gene-regulating patterns. Immune cell infiltration analysis was conducted using ssGSEA, and m<sup>6</sup>A scores were computed to quantify molecular patterns. Eleven m<sup>6</sup>A regulators were significantly differentially expressed. The top four candidate m<sup>6</sup>A regulators (FTO, YTHDF2, CBLL1, and METTL14) were identified to predict the risk of Behçet’s uveitis. A nomogram was constructed based on the four candidate m<sup>6</sup>A regulators to visualize the association between the expression levels of the candidate with the risk of onset of Behçet’s uveitis. Two distinct m<sup>6</sup>A patterns and gene patterns were identified, validated by consensus clustering. High m<sup>6</sup>A scores were associated with more severe disease stages, with differential immune cell infiltration observed between subtypes. Immune-related genes, such as LRRN3 and DAAM2, were identified as key in differentiating m<sup>6</sup>A patterns. M<sup>6</sup>A modification plays an important role in the occurrence of uveitis. Distinct m<sup>6</sup>A patterns and gene clusters highlight their potential for early diagnosis and personalized treatment.
DOI: 10.15468/dl.qgeu72
title: Occurrence Download

description: A dataset containing 366 species occurrences available in GBIF matching the query:
{
 "and" : [
 "GadmGid is REU",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Pseudoscleropodium purum (Hedw.) M.Fleisch."
 ]
}

 The dataset includes 366 records from 8 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0004591-250310093411724/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.t2y4bm
title: Occurrence Download

description: A dataset containing 5733 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Draba nemorosa L.",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "BasisOfRecord is Specimen",
 "OccurrenceStatus is Present"
 ]
}

 The dataset includes 5733 records from 219 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0004592-250310093411724/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.b2m8y4
title: Occurrence Download

description: A dataset containing 23739 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Tradescantia fluminensis Vell.)",
 "BasisOfRecord is one of (Specimen, Human Observation, Observation, Living Specimen, Machine Observation, Literature Occurrence)",
 "Geometry POLYGON((-180 -90,180 -90,180 90,-180 90,-180 -90))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "Year is greater than or equal to 1945"
 ]
}

 The dataset includes 23739 records from 270 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0004593-250310093411724/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.48670/mds-00360
title: Black Sea Waves Analysis and Forecast
DOI: 10.6084/m9.figshare.28360313
title: Supplementary File 1

description: Supplementary File 1. RoguePlots test for <i>Platydracus scriptus</i>.
DOI: 10.5517/ccdc.csd.cc2k6dck
title: CCDC 2359638: Experimental Crystal Structure Determination

description: Related Article: James E. Pearce, Jack Hodgson, Ana A. Folgueiras-Amador, Johanna A. Fish, Robert C. Carroll, Simon J. Coles, Philip J. Parsons, Richard C. D. Brown, David C. Harrowven|2025|Chem.Commun.|61|4042|doi:10.1039/D4CC06061J
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.